These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36738305)

  • 1. Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study.
    Yagi K; Maruo A; Ishida S; Aizawa F; Ushio S; Sakaguchi S; Kajizono M; Niimura T; Goda M; Hamano H; Izawa-Ishizawa Y; Zamami Y; Ishizawa K
    Clin Exp Med; 2023 Oct; 23(6):2799-2804. PubMed ID: 36738305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells.
    Ando-Matsuoka R; Yagi K; Takaoka M; Sakajiri Y; Shibata T; Sawada R; Maruo A; Miyata K; Aizawa F; Hamano H; Niimura T; Izawa-Ishizawa Y; Goda M; Sakaguchi S; Zamami Y; Yamanishi Y; Ishizawa K
    Drug Dev Res; 2023 Feb; 84(1):75-83. PubMed ID: 36484282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: A nationwide database study.
    Tsujita K; Deguchi H; Uda A; Sugano K
    J Cardiol; 2020 Jul; 76(1):51-57. PubMed ID: 32184027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study: Vonoprazan and proton pump inhibitors in
    Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
    World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect.
    Yagi K; Mitstui M; Zamami Y; Niimura T; Izawa-Ishizawa Y; Goda M; Chuma M; Fukunaga K; Shibata T; Ishida S; Sakurada T; Okada N; Hamano H; Horinouchi Y; Ikeda Y; Yanagawa H; Ishizawa K
    Cancer Med; 2021 Jan; 10(1):164-172. PubMed ID: 33231381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vonoprazan versus proton pump inhibitors for postendoscopic submucosal dissection bleeding in the stomach: a multicenter population-based comparative study.
    Shiratori Y; Niikura R; Ishii N; Ikeya T; Honda T; Hasatani K; Yoshida N; Nishida T; Sumiyoshi T; Kiyotoki S; Arai M; Kawai T; Fukuda K
    Gastrointest Endosc; 2022 Jan; 95(1):72-79.e3. PubMed ID: 34237329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study.
    Kojima Y; Takeuchi T; Sanomura M; Higashino K; Kojima K; Fukumoto K; Takata K; Sakamoto H; Sakaguchi M; Tominaga K; Higuchi K
    Digestion; 2018; 97(1):70-75. PubMed ID: 29393198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.
    Iwakiri K; Sakurai Y; Shiino M; Okamoto H; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Ashida K
    Therap Adv Gastroenterol; 2017 Jun; 10(6):439-451. PubMed ID: 28567114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
    Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vonoprazan poses no additional risk of developing Clostridioides difficile infection compared to proton pump inhibitors.
    Saruta Y; Watanabe K; Tsuji T; Takahashi Y; Matsuzawa H; Yoshida T; Takahashi S; Shimodaira Y; Matsuhashi T; Iijima K
    J Gastroenterol Hepatol; 2023 Jun; 38(6):940-947. PubMed ID: 36882162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection.
    Watanabe K; Shimodaira Y; Takahashi S; Fukuda S; Koizumi S; Matsuhashi T; Iijima K
    Am J Gastroenterol; 2021 Aug; 116(8):1632-1637. PubMed ID: 33989224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
    Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
    J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of vonoprazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: A meta-analysis.
    Liu C; Feng BC; Zhang Y; Li LX; Zuo XL; Li YQ
    J Dig Dis; 2019 Oct; 20(10):503-511. PubMed ID: 31414725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
    Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan.
    Sugawara K; Koizumi S; Horikawa Y; Mimori N; Tsuji T; Ishii H; Fujimori S; Onochi K; Watanabe H; Iijima K
    J Gastroenterol; 2019 Nov; 54(11):963-971. PubMed ID: 31037448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Use of Vonoprazan and Proton Pump Inhibitors for the Treatment of Peptic Ulcers Resulting from Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis.
    He HS; Li BY; Chen QT; Song CY; Shi J; Shi B
    Med Sci Monit; 2019 Feb; 25():1169-1176. PubMed ID: 30755541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: A systematic review with meta-analysis.
    Kang H; Kim BJ; Choi G; Kim JG
    Medicine (Baltimore); 2019 Jun; 98(24):e15860. PubMed ID: 31192917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor.
    Tack J; Vladimirov B; Horny I; Chong CF; Eisner J; Czerniak R; Takanami Y
    Neurogastroenterol Motil; 2023 Jan; 35(1):e14468. PubMed ID: 36178335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.